Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
30 May, 2017 14:49 IST
Aurobindo Pharma gets USFDA nod for anti-cough tablets
Source: IRIS | 21 Mar, 2017, 09.14AM
Comments  |  Post Comment

Aurobindo Pharma announced that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture Guaifenesin and Dextromethorphan Hydrobromide extended-release tablets, 600/30 mg and 1200/60mg (OTC). Aurobindo's Guaifenesin and Dextromethorphan Hydrobromide extended-release tablets are the AB rated generic equivalent of Reckitt Benckiser's Mucinex DM tablets. The product will be launched in Q1FY18.

Guaifenesin and Dextromethorphan Hydrobromide extended-release tablets helps loosen mucus and phlegm, and thin out bronchial secretions, making coughs more productive. The approved product has an estimated market size of US$ 235 million for the twelve months ending December 2016 according to IRI database.

This is the 106 th ANDA (including 21 tentative approvals) approved out of Unit VII formulation facility in Hyderabad, India used for manufacturing oral products. Aurobindo now has a total of 311 ANDA approvals (272 Final approvals including 16 from Aurolife Pharma LLC and 39 tentative approvals) from USFDA.

Shares of the company gained Rs 1.7, or 0.24%, to trade at Rs 704.90. The total volume of shares traded was 0 at the BSE (9.01 a.m., Tuesday).



Aurobindo Pharma Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Related Articles
Valiant Comm secures L1 status in recently concluded e-reverse auction - 30-May-2017 14:36
Paramount Comm enters into one-time settlement with SCB - 30-May-2017 14:33
NBCC's JV to develop Smart Industrial City at Raigad - 30-May-2017 14:29
Oil India quarterly profit plunges 96% - 30-May-2017 11:35
RBI hikes FII limit in Shilpa Medicare to 40% - 30-May-2017 10:40
Tata Power Solar revenue doubles to Rs 22.62 bn - 30-May-2017 10:22
8K Miles closes acquisition of US based Cornerstone Advisors Group - 30-May-2017 10:18
Larsen & Toubro bags orders worth Rs 51.46 bn - 30-May-2017 09:53
Larsen & Toubro quarterly earnings up 29.5% - 30-May-2017 08:47
BPCL quarterly earnings decline 13% - 30-May-2017 08:37
NTPC quarterly net falls 26% - 30-May-2017 08:30
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer